The strong clinical data supports potential differentiation for nimacimab in combination with incretin therapies, but the significant increase in cash burn raises concerns about future dilution risk. Traders should monitor Q4 2026 topline data from the higher-dose expansion study and finalization of the Phase 2b protocol as key catalysts.
SKYE drugs
SKYE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 11 $0.7210entry
- T+1 · 8mo ago −1.94%α −0.46% · $0.7070
- T+5 · 8mo ago −6.66%α −4.47% · $0.6730
- T+20 · 7mo ago +0.69%α +0.17% · $0.7260
- T+60 · 6mo ago +6.80%α −4.73% · $0.7700
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Skye Bioscience reported Q4 and full-year 2025 financial results, highlighting ongoing clinical progress with its obesity candidate nimacimab, including initiation of a higher-dose expansion study and FDA feedback shaping Phase 2b design. The company emphasized strong combination data with semaglutide, showing 22.3% mean weight loss at 52 weeks and favorable body composition outcomes, but reported a significant net loss increase due to higher R&D and manufacturing costs. Cash runway is expected through Q4 2026, excluding Phase 2b clinical costs.
Key Financial Metrics
Key Facts
- Initiated higher-dose CBeyond Expansion Study (Part C) with 400 mg and 600 mg IV cohorts to assess safety and pharmacokinetics; topline data expected Q4 2026.
- Received FDA Type C meeting feedback informing Phase 2b combination trial design with incretin therapy.
- Interim 52-week data: 22.3% weight loss with nimacimab + semaglutide, no plateau observed, strong safety profile maintained.
- 13-week off-treatment follow-up: combination cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone; maintained fat loss and gained lean mass.
- Q4 2025 R&D expenses: $11.5M (up from $7.8M in Q4 2024); full-year R&D: $42.4M (vs. $18.7M in 2024).
- Net loss for 2025: $55.9M (vs. $26.6M in 2024), driven by $20.7M increase in contract manufacturing costs.
- Cash, cash equivalents, and short-term investments: $25.7M as of December 31, 2025; expected to fund operations through Q4 2026, excluding Phase 2b clinical costs.
Financial Impact
Net loss nearly doubled year-over-year to $55.9M, primarily due to $20.7M increase in manufacturing costs for Phase 2a extension and anticipated Phase 2b supply. R&D spending more than doubled from 2024 to 2025.
Risk Factors
- High cash burn may necessitate future equity financing, leading to shareholder dilution.
- Phase 2b trial design and dosing strategy remain undefined; regulatory path could be delayed.
- Competitive risk from other obesity therapies in development with more advanced clinical data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253294 |
Track record
16 reports on SKYE
5 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +82.80% at T+60 after the Aug 14, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago DEFA14A Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
- Oct 26, 202621d ago PREM14A Bearish 7/10 Entry $1.45 Now $1.07 +26.55% settles Nov 24
- Oct 14, 20264w ago SC 13G Neutral 4/10 Entry $1.59 to $1.08 Now $1.07 −33.02% ▼ −32.08% −30.17% vs SPY
- Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $1.67 to $1.54 Now $1.07 −36.23% ▼ −7.78% −6.31% vs SPY
- Sep 24, 20267w ago SC 13D/A Bearish 6/10 Entry $1.67 to $1.54 Now $1.07 +36.23% ▲ +7.78% +6.31% vs SPY
- Sep 18, 20268w ago Insider Cluster Bearish 4/10 Entry $1.78 to $1.53 Now $1.07 +40.17% ▲ +14.04% +13.14% vs SPY
- Aug 19, 202612w ago DEFA14A Neutral 4/10 Entry $0.2809 to $0.2206 Now $1.07 +279.14% ▼ −21.46% −21.34% vs SPY
- Aug 14, 202613w ago 8-K Mixed 7/10 Entry $0.5015 to $0.2487 Now $1.07 +112.36% ▼ −50.40% −48.41% vs SPY
- Aug 14, 202613w ago Press Release Bearish 7/10 Entry $0.5015 to $0.2487 Now $1.07 −112.36% ▲ +50.40% +48.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers